Oncology Pharmacotherapy and Applications of Biosimilars Program

Recognizing that there is a rapid expansion of Biosimilars usage in clinical practice, and that the role of an oncology pharmacist is evolving and further integrating as a key member of a multidisciplinary healthcare team, ISOPP developed the Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) online education program that supports oncology pharmacists to safely and confidently introduce Biosimilars into their clinical practice and multidisciplinary healthcare team.

ISOPP presents this education program in a novel way by giving both fundamentals and advanced aspects of 1) pharmacotherapy of various cancers, 2) implementation of biosimilars in oncology practice and 3) interpretation of available scientific and regulatory data and pharmacist’s recommendations for using biosimilars in different cancers.

The Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program is supported by Pfizer through an educational grant.

The education program is for ISOPP Members who are oncology pharmacists and have practiced for at least one year in the area of oncology pharmacy. Registration is complimentary. Not an ISOPP member? Join ISOPP for as low as $55 CAD excluding tax, depending on where you live, and be part of leading edge education to advance your pharmacy oncology knowledge from wherever you are!

The program launched in October 2021 and consists of 10 online courses (total of 25 hours) and an opportunity to meet at ISOPP’s 2023 Symposium in Spain to expand the Biosimilars Expert Network.

We acknowledge the Faculty members, Reviewers and Task Force members for their contributions to the OPAB program.

Accreditation for this program is provided by the California Society of Health-System Pharmacists (CSHP). CSHP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.